Similarly, co-targeting of BCL-XL and MCL1 in SCLC cell lines using DT2216 (BCL-XL degrader) and AZD8055 (mTOR inhibitor) showed synergistic responses [239]. Here, MTOR is linked to small cell lung carcinoma.